Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Insurance
    • Cigna new plan to...

    Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-08T09:00:20+05:30  |  Updated On 14 Aug 2021 11:42 AM IST

    The first two gene therapies to be included in Cigna Corp's program are blindness therapy, Luxturna, and the most expensive drug in the world Novartis' $2.1 million spinal muscular atrophy treatment, Zolgensma, the insurer said.


    New Delhi: Health insurer Cigna Corp said on Thursday it had introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.


    Gene therapies, which in general aim to treat diseases by manipulating genes at a cellular level, are among the most expensive treatments in the world.


    While there are only two approved gene therapies in the United States, drugmakers have been pouring in millions of dollars into the development of these treatments that could offer a potential one-time cure to rare and life-threatening disorders.


    The first two gene therapies to be included in Cigna's program are blindness therapy, Luxturna, and the most expensive drug in the world Novartis' $2.1 million spinal muscular atrophy treatment, Zolgensma, the insurer said.


    Spark Therapeutics Inc and Novartis AG's Luxturna, the first-approved gene therapy in the United States, has been criticized for its price tag of $850,000, or $425,000 per eye.


    Additional therapies may be added to the program, and it will be able to leverage the expertise of its pharmacy benefits manager Express Scripts, which it bought for $54 billion last year, Cigna said.


    The initiative comes about a year after Reuters reported Express Scripts was in talks with biotechnology companies to have its speciality pharmaceutical business exclusively distribute their new gene therapies when they become available.


    Cigna's new program protects employers and unions against the high price shocks associated with new breakthrough therapies, the company said.


    The addressable market for ongoing gene therapy development programs could be as big as 2.4 billion patients worldwide, and is only expected to grow in size, Guggenheim analyst Whitney Ijem said in a note on Wednesday.


    Read Also: Cigna caps insulin prices at $25 for 30 days

    Biotechnology companiescignaexpensive therapygene therapiesHealth insurer Cignainsurance planLuxturnanew insuranceNovartisNovartis gene therapypharmapharma companypharma newsspinal muscular atrophy treatmentUSWhitney IjemZolgensma
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok